You are here: Industry Insights > Market News > Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:913613-82-8

Erythorbic Acid (Molecular Formula:C₆H₈O₆)

Sodium Erythorbate(Molecular Formula:C₆H₇NaO₆·H₂O)

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

biospaceNovember 23, 2017

Tag: NHS , Concordia

Favorites

Concordia International, the Canadian drug company, has overcharged the NHS by more than £100m in the past decade for a life-changing thyroid drug, according to Britain’s competition watchdog.

The Competition and Markets Authority (CMA) said it had provisionally found that Concordia had "abused its dominant position to overcharge the NHS" by hiking the price of liothyronine, used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017.

The regulator said the NHS had spent more than £34m on the drug last year, up from about £600,000 in 2006.

Previous:FDA approves first implanted lens that can be adjusted after cataract surgery to improve vision with

Next:Merck to suspend filing Ebola vaccine for FDA approval until next year

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>